Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025181 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00025181 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 19 participants.
The verdict
NCT00025181, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy and vaccine therapy in treating patients who have stage III or stage IV melanoma that has been removed during surgery.
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL ipilimumab
- BIOLOGICAL tyrosinase peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2001-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025181
The ClinicalTrials.gov registry entry for NCT00025181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00025181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025181 about?
NCT00025181 is a clinical study titled "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effec...
What is the current status of trial NCT00025181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2001-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00025181?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), MART-1 antigen (BIOLOGICAL), ipilimumab (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00025181?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.